Darby Overseas Investments, the private equity arm of Franklin Templeton Investments, has exited its investment in India-based active pharmaceutical ingredients manufacturer Symbiotec Pharmalab to pan-emerging markets private equity firm Actis. Last month, Actis invested US$48 million for a significant minority stake in the company and has subsequently increased its holding by buying Darby’s interest. Darby originally invested INR450 million (approximately US$9.8 million) in September 2011, structured through Franklin Templeton Private Equity Strategy fund. Financial details of the transaction were not disclosed.